Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMN4QSW)

Drug Name
CI-949 Drug Info
Synonyms
CI 949; UNII-EM1J51043X; EM1J51043X; L-Arginine, compd. with 5-methoxy-3-(1-methylethoxy)-1-phenyl-N-1H-tetrazol-5-yl-1H-indole-2-carboxamide (1:1); OHOCQQJBKBVAFF-VWMHFEHESA-N; AC1L4M1L; AC1Q5G9U; 121530-58-3; SCHEMBL17041896; n5-(diaminomethylidene)-l-ornithine- 5-methoxy-1-phenyl-3-(propan-2-yloxy)-n-(2h-tetrazol-5-yl)-1h-indole-2-carboxamide(1:1); LS-21607; 5-Methoxy-3-(1-methylethoxy)-1-phenyl-N-1H-tetrazol-5-yl-1H-indole-2-carboxamide L-arginate salt; (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid
Indication
Disease Entry ICD 11 Status REF
Asthma CA23 Discontinued in Phase 2 [1]
Cross-matching ID
PubChem CID
159563
CAS Number
CAS 104961-19-5
TTD Drug ID
DMN4QSW

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Leukotriene B4 receptor 1 (LTB4R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LTB4 DME26RS Human immunodeficiency virus infection 1C62 Phase 2 [3]
Amelubant DMUMCB9 Pulmonary disease 1B10-1F85 Phase 2 [4]
Biomed 101 DMQ9KZW Kidney cancer 2C90.0 Phase 1 [5]
LY293111 DM03FHA Pancreatic cancer 2C10 Discontinued in Phase 2 [6]
SB-201993 DMIF4VJ Psoriasis vulgaris EA90 Discontinued in Phase 2 [7]
CP-195543 DM1OSUR Rheumatoid arthritis FA20 Discontinued in Phase 2 [8]
LTB 019 DM6G0PN Asthma CA23 Discontinued in Phase 2 [9]
LY-223982 DMWB7DO Asthma CA23 Discontinued in Phase 2 [10]
CP-105696 DM1C4IN Inflammatory bowel disease DD72 Discontinued in Phase 1 [11]
TAK-683 DMRD8HK Prostate cancer 2C82.0 Discontinued in Phase 1 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leukotriene B4 receptor 1 (LTB4R) TTN53ZF LT4R1_HUMAN Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000104)
2 Inhibition of histamine, leukotriene C4/D4, and thromboxane B2 release from human leukocytes and human chopped lung mast cells by the allergic mediator release inhibitor, CI-949. J Allergy Clin Immunol. 1990 Dec;86(6 Pt 1):902-8.
3 LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes. Nat Med. 2015 Mar;21(3):239-47.
4 Leukotriene receptor antagonists in children with cystic fibrosis lung disease : anti-inflammatory and clinical effects. Paediatr Drugs. 2005;7(6):353-63.
5 Biomed 101, a leukotriene B4 inhibitor, may decrease IL-2 toxicity. 2003 ASCO Annual Meeting. 2003.
6 The Role of PPARgamma Receptors and Leukotriene B(4) Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer. PPAR Res. 2008;2008:827096.
7 (E)-3-[6-[[(2,6-dichlorophenyl)thio]methyl]-3-(2-phenylethoxy)-2- pyridinyl]-2-propenoic acid: a high-affinity leukotriene B4 receptor antagonist w... J Med Chem. 1996 Sep 13;39(19):3837-41.
8 The synthesis of CP-195543, an LTB4 antagonist for the treatment of inflammatory diseases. Curr Opin Drug Discov Devel. 1999 Nov;2(6):550-6.
9 Effect of the oral leukotriene B4 receptor antagonist LTB019 on inflammatory sputum markers in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2008;21(2):409-17.
10 Specific inhibition of leukotriene B4-induced neutrophil activation by LY223982. J Pharmacol Exp Ther. 1992 Dec;263(3):1009-14.
11 3-Substituted-4-hydroxy-7-chromanylacetic acid derivatives as antagonists of the leukotriene B4 (LTB4) receptor, Bioorg. Med. Chem. Lett. 7(17):2307-2312 (1997).
12 A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J Exp Med. 2000 Aug 7;192(3):421-32.